What Is Sermorelin?
Sermorelin is a synthetic peptide made from the first 29 amino acids of human growth-hormone-releasing hormone. This natural hormone is produced in the brain and tells the pituitary, a small gland beneath the brain, to release growth hormone.
Sermorelin was previously available in the United States as the prescription product Geref. It was used to test growth-hormone release and to promote growth in some children with growth-hormone deficiency. Its manufacturer later stopped selling it. There is no current sermorelin product approved by the US Food and Drug Administration (FDA), which regulates medicines in the United States. Some clinics promote compounded versions, which are specially prepared by pharmacies rather than supplied as an FDA-approved finished product, for adult hormone treatment and anti-ageing.
What is growth-hormone-releasing hormone?
Growth-hormone-releasing hormone, shortened to GHRH, is made in a part of the brain called the hypothalamus. The hypothalamus helps coordinate hormones, temperature, appetite, sleep and other basic functions.
GHRH travels a short distance to the pituitary gland, a small gland beneath the brain. It binds to the GHRH receptor. A receptor is a protein that receives a biological signal and changes how a cell behaves.
This signal causes the pituitary to release growth hormone in pulses. A pulse is a brief rise rather than a constant level. The largest natural releases often occur during sleep.
Growth hormone supports normal childhood growth and affects metabolism, bone, muscle and other tissues. It also prompts the liver and other tissues to produce insulin-like growth factor 1, usually shortened to IGF-1. IGF-1 is another hormone involved in growth and tissue activity.
How is sermorelin related to natural GHRH?
Complete human GHRH contains 44 amino acids. Researchers found that its first 29 amino acids retain the main ability to stimulate growth-hormone release. Sermorelin is a synthetic version of this shorter section.
For this reason, it is called GHRH(1-29) or growth-hormone-releasing factor 1-29. “Analogue” means that it was designed to resemble a natural biological molecule.
Sermorelin does not contain growth hormone. It asks a functioning pituitary gland to release the body's own hormone. If the pituitary cannot respond, the signal may produce little or no useful effect.
How does sermorelin work?
Sermorelin binds to GHRH receptors on cells in the pituitary gland. This starts a signalling process that releases stored growth hormone into the blood.
The hormone response is limited by the person's pituitary capacity and the body's feedback systems. In a feedback system, rising hormone levels signal the brain and pituitary to adjust further release. Somatostatin, another natural hormone, can reduce growth-hormone release. IGF-1 and growth hormone also feed information back to the brain and pituitary.
This is why sermorelin and manufactured human growth hormone are not interchangeable. Sermorelin stimulates a signal upstream of growth hormone. Manufactured growth hormone supplies the final hormone directly.
That theoretical difference does not prove that sermorelin is safer or more appropriate for wellness use. Safety and benefit must be tested in the people and conditions for which a treatment is proposed.
What was Geref?
Geref was a prescription sermorelin acetate product sold in the United States by EMD Serono, Inc., a pharmaceutical company. The acetate part describes the chemical salt form used in the finished medicine.
The product had two medical roles. One formulation was used as a diagnostic test, meaning a test that helped doctors assess whether the pituitary could release growth hormone. Another was used to treat certain children with poor growth associated with inadequate growth-hormone release.
EMD Serono told the FDA in 2008 that it was discontinuing the Geref products and asked the agency to withdraw their approvals. The FDA withdrew the approvals in 2009. After reviewing its records and the available safety information, the FDA stated in 2013 that Geref had not been withdrawn for reasons of safety or effectiveness.
That history does not leave a current approval attached to every sermorelin product. FDA approval applies to a specific finished medicine, manufacturer, formulation and use. There is no currently marketed FDA-approved sermorelin medicine, and a product prepared by a compounding pharmacy does not become Geref by containing the same peptide.
How was sermorelin used as a diagnostic test?
Growth-hormone deficiency can be difficult to diagnose because the hormone is released in pulses. A single random blood measurement can be low even in someone whose pituitary works normally.
A stimulation test gives a substance intended to prompt growth-hormone release, then measures blood samples over time. Doctors can use the response alongside growth history, IGF-1, other hormones and clinical findings.
Historical research used an intravenous sermorelin level of 1 microgram per kilogram of body weight. Intravenous means delivered into a vein. A microgram is one-millionth of a gram, and “per kilogram” means the research amount was adjusted to body weight.
These details describe a medically supervised diagnostic protocol. They are not instructions for personal use.
Studies suggested that sermorelin testing produced fewer false-positive results than some older stimulation tests. A false positive occurs when a test incorrectly suggests that a person has a condition.
What did the main childhood treatment study find?
A 1996 study by the Geref International Study Group enrolled 110 previously untreated prepubertal children with growth-hormone deficiency. Prepubertal means before the physical changes of puberty. The study was multicentre, meaning that more than one medical centre took part, and open-label, meaning the families and researchers knew which treatment the children received. Eighty-six of the 110 children were included in the main analysis of how well the treatment worked.
The children received once-daily sermorelin under the skin at a documented research level of 30 micrograms per kilogram. The study continued for up to one year. There was no placebo group, so each child's growth during treatment was compared mainly with their growth before treatment.
The researchers measured growth speed, progress in bone development and safety every three to six months. Among the children included in the main analysis, average growth speed rose from about 4.1 centimetres per year before treatment to 8.0 centimetres per year after six months. It was about 7.2 centimetres per year at twelve months.
The result shows that sermorelin could accelerate growth in some children whose pituitary glands could respond. It does not show that every child benefited equally, and the absence of a randomised comparison group makes it harder to separate treatment effects from other influences.
Randomised means assigning participants to groups by chance. This helps prevent differences between the groups from biasing the result. A placebo is an inactive comparison designed to resemble the treatment.
The study administration level is included as clinical history, not as a current dosage recommendation.
What did other childhood studies find?
A separate 1994 study examined 18 prepubertal children with idiopathic short stature. “Idiopathic” means that no specific cause had been identified. These children were short but were not considered deficient in growth hormone.
Participants received a GHRH analogue twice daily for twelve months at a research level of 20 micrograms per kilogram. Their growth rate increased during treatment, then returned towards the earlier rate after treatment stopped.
This finding suggests that stimulating the pathway can temporarily increase growth in some children. It does not establish a permanent increase in adult height, nor does it support use in healthy adults.
Another small study tested intranasal GHRH in children with growth-hormone deficiency. Intranasal means applied inside the nose. The results helped researchers understand hormone responses but did not establish the nasal route as a modern standard treatment.
Has sermorelin been studied in older adults?
Researchers have studied GHRH analogues in older adults because growth-hormone and IGF-1 levels generally decline with age. These studies are often used to market sermorelin as an anti-ageing treatment, but the details require care.
A 1997 trial included 19 adults aged 55 to 71. Its purpose was to examine hormone levels, body composition, sleep and other possible effects of restoring GHRH signalling in older adults. Participants first received placebo and then a nightly GHRH analogue for sixteen weeks. The placebo provided an inactive comparison. The analogue was not the ordinary commercial sermorelin molecule because one amino acid had been changed to alter its properties.
The study reported higher overnight growth-hormone and IGF-1 measurements. Skin thickness increased in men and women. Men, but not women, showed some changes in lean body mass, insulin sensitivity, general wellbeing and libido. Sleep quality did not improve in either group.
Lean body mass means everything in the body except fat, and does not necessarily mean functional muscle gain. Insulin sensitivity describes how effectively the body responds to insulin, the hormone that helps move glucose from blood into cells.
The trial was very small, lasted four months and used a modified GHRH analogue. It cannot establish that current compounded sermorelin reverses ageing, improves health or is safe for long-term use.
The Orentra Research Methodology explains why participant numbers, comparison groups and the exact molecule tested matter when assessing a study.
Is sermorelin FDA approved today?
No currently marketed sermorelin product has FDA approval.
The FDA previously approved the finished Geref products. EMD Serono later stopped supplying them. Products now prepared by compounding pharmacies are not Geref and do not inherit its approval.
Compounding means a licensed pharmacy prepares a medicine for an individual patient when an approved product does not meet a particular clinical need. Compounded medicines are not reviewed and approved by the FDA in the same way as finished commercial medicines.
A clinician may prescribe a compounded product in circumstances allowed by US law, but that fact does not prove the broad anti-ageing claims used in advertising.
What benefits are claimed, and what does the evidence support?
| Common claim | What the evidence supports |
|---|---|
| Stimulates growth-hormone release | Established in human testing when the pituitary can respond |
| Helps some children grow | Historical studies reported increased growth rate in selected children; the approved product is no longer marketed |
| Diagnoses growth-hormone deficiency | Historically used as a stimulation test; current diagnostic practice has changed |
| Builds muscle in healthy adults | No strong modern trial establishes meaningful functional muscle gain |
| Reduces body fat | Limited GHRH-analogue research does not establish sermorelin as a weight-loss treatment |
| Improves sleep | Small older-adult research did not show improved sleep quality |
| Reverses ageing | No clinical trial shows that sermorelin reverses ageing or extends life |
| Improves recovery | Adequate controlled evidence in healthy adults is lacking |
What side effects were associated with sermorelin?
Historical product information and studies reported reactions including pain, redness or swelling at the injection site, flushing, headache, dizziness, sleepiness and changes in taste.
Because sermorelin stimulates the growth-hormone pathway, clinicians also considered effects on blood glucose, fluid balance, joints and other hormone systems. The response may differ in people with pituitary disease or other medical conditions.
The historical data do not provide a complete safety guarantee for present-day compounded products, different patterns of use or long-term anti-ageing use. A compounded product may contain the wrong substance or amount, unwanted contaminants or bacteria, or may not remain stable as expected.
Is sermorelin safer than growth hormone?
There is no simple answer.
Sermorelin depends on the pituitary gland and natural feedback, while manufactured human growth hormone enters the body directly. This provides a biological reason why their patterns of exposure may differ.
It does not prove that sermorelin is generally safer. Comparative safety depends on the condition, product, administration, monitoring and person. Modern approved growth-hormone products have current prescribing information and manufacturing oversight. Current compounded sermorelin products do not have an FDA-approved label.
How does sermorelin differ from ipamorelin?
Sermorelin copies part of GHRH and activates the GHRH receptor. Ipamorelin activates the ghrelin receptor, another pathway that can prompt growth-hormone release.
Sermorelin has a history as a finished approved medicine and has been studied in children. Ipamorelin has much more limited human evidence and was not approved as a medicine.
Their effects cannot be compared by milligrams, and popular combinations have not been shown in adequate trials to improve health or reduce risk.
How does sermorelin differ from tesamorelin?
Both are analogues of GHRH, but they are not the same molecule or medicine.
Tesamorelin is a modified 44-amino-acid GHRH analogue. A current FDA-approved tesamorelin product is used for a specific condition involving excess abdominal fat in adults with HIV. Sermorelin contains 29 amino acids and has no current approved US product.
An approval for tesamorelin cannot be transferred to sermorelin.
Is sermorelin prohibited in sport?
Growth-hormone-releasing factors are prohibited under World Anti-Doping Agency rules. Athletes should check the current prohibited list and the rules applying to their sport.
Frequently asked questions
Is sermorelin a peptide?
Yes. It is a synthetic chain of 29 amino acids based on the active beginning of human GHRH.
Is sermorelin growth hormone?
No. It sends a signal to the pituitary gland to release growth hormone. It does not supply growth hormone directly.
Is sermorelin FDA approved?
The Geref product was previously approved but discontinued. No currently marketed sermorelin product is FDA approved.
Why was sermorelin discontinued?
EMD Serono stopped supplying Geref and asked the FDA to withdraw its approvals. The FDA later determined that the products had not been withdrawn for reasons of safety or effectiveness.
Does sermorelin build muscle or reduce fat?
There is no strong modern clinical evidence establishing those benefits in healthy adults.
Does sermorelin improve sleep?
Growth-hormone release is related to sleep, but a small older-adult GHRH-analogue trial did not find improved sleep quality.
Is compounded sermorelin the same as Geref?
No. A compounded preparation is not the discontinued FDA-approved finished product and does not inherit its approval.
Can sermorelin be combined with ipamorelin?
This article provides no advice about combining peptides, sometimes called stacking. Adequate trials with comparison groups have not established the benefit or safety of commonly marketed combinations.
What is sermorelin acetate?
It is a chemical form in which sermorelin is paired with acetate. The name alone does not establish approval, product quality or that it is equivalent to the former Geref medicine.
What the evidence supports today
Sermorelin has real human evidence and a genuine medical history. It can stimulate growth-hormone release, was used as a diagnostic agent and increased growth rate in some children.
Its current marketing often moves far beyond that evidence. The approved Geref product disappeared from the market years ago. Small studies of GHRH analogues in older adults do not establish that compounded sermorelin reverses ageing, improves sleep, builds useful muscle or produces long-term health benefits.
Sermorelin is a biologically active GHRH analogue with historical medical uses, but there is no current FDA-approved product and the evidence does not support many modern wellness claims.
Sources
Research reviewed through September 2026.